Immix Biopharma (IMMX) Other Non-Current Liabilities (2020 - 2021)
Immix Biopharma (IMMX) reported Other Non-Current Liabilities of $23.4 million for Q4 2021, up 3972.14% on a YoY basis from $575000.0 in Q4 2020, and up 3972.14% sequentially from $575000.0 in Q4 2020.
Immix Biopharma (IMMX) Other Non-Current Liabilities (2020 - 2021) Analysis & Trends
Immix Biopharma (IMMX) has 2 years of Other Non-Current Liabilities data on file, last reported at $23.4 million in Q4 2021.
- For the quarter ending Q4 2021, Other Non-Current Liabilities rose 3972.14% year-over-year to $23.4 million; the trailing twelve-month figure through Dec 2021 stood at $23.4 million (up 3972.14% YoY), and the FY2021 full-year result was $23.4 million, up 3972.14% from the prior year.
- Other Non-Current Liabilities grew to $23.4 million in Q4 2021, from $575000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $23.4 million in Q4 2021 to a low of $575000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Immix Biopharma | 487.25 Mn | 487.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 23.41 Mn |
| Dec 31, 2020 | 575,000.00 |